ReferenceRRK5273

ROSCO

Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer: A randomised phase III stratified biomarker trial of neo-adjuvant 5-Fluorouracil Epirubicin and Cyclophosphamide vs Docetaxel and Cyclophosphamide chemotherapy

Research Summary

Research Overview
PI Name Rea - DW
Speciality
Sponsor University of Birmingham
Project Status Open
Proposed End Date 01/01/2025
Study Run through CRF? Yes
Target number of patients agreed to recruit 75
Recruitment so far 61